Trial Profile
A Phase I Study to Evaluate the Safety and Tolerability, of the Aminopeptidase Inhibitor, CHR-2797, in Patients With Advanced Tumours
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Aug 2010
Price :
$35
*
At a glance
- Drugs Tosedostat (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Chroma Therapeutics
- 04 Jul 2008 New trial record.